New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
10:41 EDTTA, IMUC, MWW, DYN, GCI, RMBS, EXH, RNGHigh option volume stocks
High option volume stocks: MWW RNG VGK GCI IMUC EXH DYN TA GREK RMBS
News For MWW;RNG;GCI;IMUC;EXH;DYN;TA;RMBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
14:06 EDTGCINY Daily News hires Lazard to explore sale, Buzzfeed reports
Subscribe for More Information
10:19 EDTEXHHigh option volume stocks
Subscribe for More Information
10:00 EDTMWWOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:24 EDTEXHExterran says on track to complete split in second half of 2015
Subscribe for More Information
07:22 EDTEXHExterran reports Q4 EPS ex-items 31c, consensus 36c
Subscribe for More Information
06:05 EDTMWWMonster Worldwide initiated with a Buy at B. Riley
Subscribe for More Information
February 24, 2015
17:02 EDTDYNDynegy reports Q4 net loss $104M vs. $91M last year
Dynegy reported Q4 consolidated Adjusted EBITDA of $67M, compared to $63M last year. Dynegy updated its 2015 guidance target using February 10 price curves. It said, "Given the later than expected acquisition closing dates, Dynegy has revised its 2015 guidance targets to a range of $825 million to $1,025 million in consolidated full year Adjusted EBITDA and $100 million to $300 million in Free Cash Flow, prior to acquisition-related costs and discretionary capital expenditures. Whereas prior guidance estimates assumed a January 1 close, new guidance estimates assume an April 1 close for the pending Duke Midwest, EquiPower and Brayton Point transactions."
10:48 EDTTARussell Glass urging TravelCenters to sell real estate, Bloomberg reports
Subscribe for More Information
February 19, 2015
09:59 EDTMWWOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
07:42 EDTMWWMonster Worldwide upgraded at Evercore ISI
Subscribe for More Information
06:20 EDTMWWMonster Worldwide upgraded to Buy from Hold at Evercore ISI
Subscribe for More Information
February 18, 2015
16:29 EDTIMUCImmunoCellular appoints Dr. Swanson to lead Stem-to-T-cell research program
ImmunoCellular Therapeutics announced the appointment of Steven Swanson, PhD, as SVP, Research. Dr. Swanson will lead the company's Stem-to-T-cell research program, which utilizes the patient's own hematopoietic stem cells to drive production of antigen-specific killer T-cells which then attack cancer cells. He will be responsible for all programmatic research and development, with the goal of identifying and advancing novel antigen-specific Stem-to-T-cell product candidates to the clinic. Prior to joining ImmunoCellular, Dr. Swanson was an independent consultant advising biopharmaceutical companies on basic immunology research, bioanalytical procedures, immunogenicity assessment, regulatory affairs and product quality.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use